IntraBiotics Shares Rise on FDA Decision
From Associated Press
IntraBiotics Pharmaceuticals Inc. stock more than doubled to a 52-week high after federal regulators gave fast-track status to the company’s only drug, iseganan, to reduce the onset of pneumonia in people on mechanical ventilators.
Shares of Palo Alto-based IntraBiotics traded up 110%, or $4.10, at $7.80 on Nasdaq.
